Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.35 |
| ▸ | DHODH | Q02127 | 3/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13423903 | 0.94 | NR3C2 (0.39) | NR3C2MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13423906 | 0.90 | WNT3A (0.39) | MEN1KMT2ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL13423905 | 0.84 | WNT3A (0.40) | SMN1; SMN2ALDH1A1HPGDADORA2AADORA1 | |
| SCHEMBL2359449 | 0.77 | ALDH1A1 (0.53) | NR3C2MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13423902 | 0.77 | DRD4 (0.39) | NR3C2SLC5A1ADORA2AADORA1 | |
| SCHEMBL13423952 | 0.76 | ALDH1A1 (0.41) | NR3C2MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13424058 | 0.75 | RIPK1 (0.44) | NR3C2SMN1; SMN2DHODH | |
| SCHEMBL13424054 | 0.74 | ALDH1A1 (0.39) | NR3C2MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13423964 | 0.72 | MAPT (0.42) | MEN1KMT2ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL13424088 | 0.72 | HTR2C (0.47) | MEN1KMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350084-B1 | TETRA-AZA-HETEROCYCLES AS PHOSPHATIDYLINOSITOL-3-KINASES (PI3-KINASES) INHIBITOR | BOEHRINGER INGELHEIM INT (DE) | 2015-06-24 | — | — | EP | disclosed |
| US-8653097-B2 | Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (P13-kinases) inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8653097-B2 | Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (P13-kinases) inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20110312940-A1 | TETRA-AZA-HETEROCYCLES AS PHOSPHATIDYLINOSITOL-3-KINASES (P13-KINASES) INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312940-A1 | TETRA-AZA-HETEROCYCLES AS PHOSPHATIDYLINOSITOL-3-KINASES (P13-KINASES) INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| WO-2010043676-A1 | TETRA-AZA-HETEROCYCLES AS PHOSPHATIDYLINOSITOL-3-KINASES (PI3-KINASES) INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312940-A1 | TETRA-AZA-HETEROCYCLES AS PHOSPHATIDYLINOSITOL-3-KINASES (P13-KINASES) INHIBITOR | CCNK, CDK1, CDKN1A | NR3C2 1291/4885MEN1 878/4885KMT2A 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.